Promega Launches Live-Cell Platform to Expand Druggable Proteome…

Event summary

Promega debuts TarSeer™ BRETSA™ Target Engagement System at SLAS 2026, enabling live-cell analysis of understudied proteins.
Technology measures ligand-protein interactions via protein denaturation, addressing gaps in cellular assays for intractable targets.
Platform applied to over 20 target classes and multiple cellular compartments.
Presentation scheduled for February 10, 2026, at SLAS International Conference in Boston.

The big picture

Promega's launch addresses a critical bottleneck in drug discovery: the lack of cellular assays for understudied proteins. By enabling live-cell analysis, the platform could unlock new therapeutic avenues within the human proteome. The technology complements Promega's existing NanoBRET® system, expanding its toolkit for small-molecule drug development.

What we're watching

Adoption Pace: How quickly drug discovery teams integrate BRETSA into workflows for previously intractable targets.
Competitive Response: Whether rivals like PerkinElmer or Thermo Fisher develop comparable live-cell target engagement platforms.
Pipeline Impact: The extent to which BRETSA accelerates validation of early-stage compounds against novel protein targets.